Lung cancer and cyclooxygenase-2

Annals of Thoracic Surgery

Volumn 76, Issue 4, 2003, Pages 1327-1335

  Castelao, J Esteban ^a   Bart III, Robert D ^a   DiPerna, Costanzo A ^a   Sievers, Eric M ^a   Bremner, Ross M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GROWTH FACTOR; PROSTAGLANDIN;

ANGIOGENESIS; APOPTOSIS; CANCER DIAGNOSIS; CANCER INVASION; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CAUSE OF DEATH; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; KIDNEY BLOOD FLOW; LUNG CANCER; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; REVIEW;

EID: 0141562299     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)00334-5     Document Type: Article

References (89)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Carney DN. Lung cancer-time to move on from chemotherapy [comment]. N Engl J Med 2002;346:126-8.
3. Jassem J, Skokowski J, Dziadziuszko R, et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg 2000;119:1141-6.
4. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
5. Ahrendt SA, Yang SC, Wu L, et al. Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardiovasc Surg 2002;123:466-74.
6. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7.
7. Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001;93:1385-91.
8. Lippman SM, Spitz MR. Lung cancer chemoprevention: an integrated approach. J Clin Oncol 2001;19:74S-82S.
9. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998;90:1609-20.
10. International Agency for Research on Cancer (IARC). In IARC, ed. IARC handbooks of cancer prevention, non-steroidal anti-inflammatory drugs. Washington DC: IARC Press, 1997:43-102.
11. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
12. O'Banion MK, Sadowski HB, Winn V, et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7.
13. Herschman HR. Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 1991;60:281-319.
14. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
15. DuBois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease [comment]. FASEB J 1998;12:1063-73.
16. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
17. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
18. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9.
19. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12.
20. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
21. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-40.
22. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells [Erratum appears in Cell 1998;94(2):following271.]. Cell 1998;93:705-16
23. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-8.
24. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
25. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-96.
26. Vainio H. Is COX-2 inhibition a panacea for cancer prevention? Int J Cancer 2001;94:613-4.
27. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
28. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000;30:73-81.
29. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
30. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
31. DiPerna CA, Bart RD, Ma Y, et al. Cyclooxygenase-2 expression in human bronchioloalveolar carcinoma. Chest 2002;122:165s.
32. Ochiai M, Oguri T, Isobe T, et al. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues, and non-small cell lung cancers. Jpn J Cancer Res 1999;90:1338-43.
33. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
34. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
35. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 1997;18:1001-6.
36. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998;58:5354-60.
37. Levin G, Kariv N, Khomiak E, et al. Indomethacin inhibits the accumulation of tumor cells in mouse lungs and subsequent growth of lung metastases. Chemotherapy 2000;46:429-37.
38. Yao R, Rioux N, Castonguay A, et al. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res 2000;26:731-42.
39. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
40. Tsubouchi Y, Mukai S, Kawahito Y, et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 2000;20:2867-72.
41. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis, and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-11.
42. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to pre-operative paclitaxel/carboplatin in early stage non-small cell lung cancer. American Society of Clinical Oncologists abstracts 2002. Available at: http://www.asco.org/ac/1,1003,_12-002324-00_18-002002-00_19-00101-00_29-00A,00. asp.
43. Csiki I, Dang T, Gonzalez A, et al. Cyclooxygenase-2 (COX-2) inhibition + docetaxel (Txt) in recurrent non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (THO-0054). American Society of Clinical Oncologists abstracts 2002. Available at: http://www.asco.org/ac/1,1003,_12-002324-00_18-002002-00_19-001187-00_29-00A,00. asp.
44. Subbaramaiah K, Hart JC, Norton L, et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERKI/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 2000;275:14838-45.
45. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study [comment]. Epidemiology 1994;5:138-46.
46. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al. Aspirin and lung cancer in women [comment]. Br J Cancer 2002;87:49-53.
47. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-6.
48. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998;95:681-6.
49. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
50. Sinicrope FA, Ruan SB, Cleary KR, et al. bcl-2, and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
51. Lin MT, Lee RC, Yang PC, et al. Cyclooxygenase-2 inducing Mcl-l-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001;276:48997-9002.
52. Blank KR, Rudoltz MS, Kao GD, et al. The molecular regulation of apoptosis and implications for radiation oncology. Int J Radiat Biol 1997;71:455-66.
53. Milas L, Gregoire V, Hunter N, et al. Radiation-induced apoptosis in tumors. Effect of radiation modulating agents. Adv Exp Med Biol 1997;400B:559-64.
54. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42-9.
55. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001;7:2998-3005.
56. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
57. Lu X, Xie W, Reed D, et al. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 1995;92:7961-5.
58. Hara A, Yoshimi N, Niwa M, et al. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 1997;88:600-4.
59. Li M, Lotan R, Levin B, et al. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000;9:545-9.
60. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000;20:2625-31.
61. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
62. Elder DJ, Halton DE, Hague A, et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2) -selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679-83.
63. Zhang X, Morham SG, Langenbach R, et al. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts [comment]. J Exp Med 1999;190:451-9.
64. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-15.
65. Lim JT, Piazza GA, Han EK, et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 1999;58:1097-107.
66. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta [comment]. Nature 1998;396:77-80.
67. Berman KS, Verma UN, Harburg G, et al. Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin Cancer Res 2002;8:354-60.
68. Liu XH, Yao S, Kirschenbaum A, et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245-9.
69. Shureiqi I, Chen D, Lotan R, et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000;60:6846-50.
70. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998;95:681-6.
71. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
72. Cao Y, Pearman AT, Zimmerman GA, et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000;97:11280-5.
73. Chang HC, Weng CF. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol Rep 2001;8:1321-5.
74. Song X, Lin HP, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells [comment]. J Natl Cancer Inst 2002;94:585-91.
75. Nie D, Honn KV. Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci 2002;59:799-807.
76. Nie D, Lamberti M, Zacharek A, et al. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 2000;267:245-51.
77. Ashton AW, Yokota R, John G, et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem 1999;274:35562-70.
78. Mayer B, Johnson JP, Leitl F, et al. E-cadherin expression in primary, and metastatic gastric cancer. Down-regulation correlates with cellular differentiation and glandular disintegration. Cancer Res 1993;53:1690-5.
79. Shattuck-Brandt RL, Lamps LW, Heppner Goss KJ, et al. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog 1999;24:177-87.
80. Doki Y, Shiozaki H, Tahara H, et al. Correlation between E-cadherin expression, and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res 1993;53:3421-6.
81. Byers SW, Sommers CL, Hoxter B, et al. Role of E-cadherin in the response of tumor cell aggregates to lymphatic, venous, and arterial flow. Measurement of cell-cell adhesion strength. J Cell Sci 1995;108:2053-64.
82. Dempke W, Rie C, Grothey A, et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001;127:411-7.
83. Attiga FA, Fernandez PM, Weeraratna AT, et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000;60:4629-37.
84. Pan MR, Chuang LY, Hung WC. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Letters 2001;508:365-8.
85. Huang M, Sharma S, Mao JT, et al. Non-small cell lung cancer-derived soluble mediators, and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription, and protein production. J Immunol 1996;157:5512-20.
86. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes, and macrophages. Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
87. Sharma S, Stolina M, Lin Y, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell, and APC function. J Immunol 1999;163:5020-8.
88. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
89. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001;276:20809-12.